CN1427720A - 用于治疗耐受性和依赖性的促代谢谷氨酸受体拮抗剂 - Google Patents

用于治疗耐受性和依赖性的促代谢谷氨酸受体拮抗剂 Download PDF

Info

Publication number
CN1427720A
CN1427720A CN01808891A CN01808891A CN1427720A CN 1427720 A CN1427720 A CN 1427720A CN 01808891 A CN01808891 A CN 01808891A CN 01808891 A CN01808891 A CN 01808891A CN 1427720 A CN1427720 A CN 1427720A
Authority
CN
China
Prior art keywords
mglur5
dependence
tolerance
treatment
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN01808891A
Other languages
English (en)
Chinese (zh)
Inventor
M·科尔斯
F·康奎特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9887294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN1427720(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN1427720A publication Critical patent/CN1427720A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicinal Preparation (AREA)
  • Fertilizers (AREA)
CN01808891A 2000-03-09 2001-03-09 用于治疗耐受性和依赖性的促代谢谷氨酸受体拮抗剂 Pending CN1427720A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0005700.0 2000-03-09
GBGB0005700.0A GB0005700D0 (en) 2000-03-09 2000-03-09 Therapy

Publications (1)

Publication Number Publication Date
CN1427720A true CN1427720A (zh) 2003-07-02

Family

ID=9887294

Family Applications (1)

Application Number Title Priority Date Filing Date
CN01808891A Pending CN1427720A (zh) 2000-03-09 2001-03-09 用于治疗耐受性和依赖性的促代谢谷氨酸受体拮抗剂

Country Status (16)

Country Link
US (1) US20030195139A1 (enExample)
EP (1) EP1267869B1 (enExample)
JP (1) JP2003525902A (enExample)
CN (1) CN1427720A (enExample)
AT (1) ATE267013T1 (enExample)
AU (1) AU783869B2 (enExample)
CA (1) CA2402341A1 (enExample)
DE (1) DE60103384T2 (enExample)
DK (1) DK1267869T3 (enExample)
ES (1) ES2220727T3 (enExample)
GB (1) GB0005700D0 (enExample)
NZ (1) NZ521228A (enExample)
PT (1) PT1267869E (enExample)
SE (1) SE1267869T5 (enExample)
TR (1) TR200401862T4 (enExample)
WO (1) WO2001066113A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116981456A (zh) * 2020-12-14 2023-10-31 诺华股份有限公司 mGluR5拮抗剂用于治疗赌博障碍的用途

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004024150A2 (en) * 2002-09-10 2004-03-25 Novartis Ag Mglu receptors antagonists for treating disorders associated with mglu receptors including addiction and depression
EP2201963B1 (en) 2005-04-05 2016-01-27 Yale University Glutamate modulating agents in the treatment of mental disorders
US20060264381A1 (en) * 2005-05-05 2006-11-23 Bear Mark F Methods of treating obsessive compulsive disorder
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
US7531541B2 (en) * 2005-09-20 2009-05-12 Vanderbilt University Partial mGluR5 antagonists for treatment of anxiety and CNS disorders
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
WO2007053596A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
DE102005062985A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
WO2007134077A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. 5 ht receptor mediated neurogenesis
WO2007134136A2 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
EP2068872A1 (en) 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
PL2083811T3 (pl) 2006-11-22 2017-05-31 Clinical Research Associates, Llc Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US20130058915A1 (en) 2010-03-02 2013-03-07 Children's Medica Center Corporation Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US20110294879A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
WO2012009646A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
WO2012054724A1 (en) 2010-10-21 2012-04-26 Massachusetts Institute Of Technology Methods of treating seizure disorders
US20130123254A1 (en) * 2011-09-30 2013-05-16 Barbara Biemans Pharmaceutically acceptable mglur5 positive allosteric modulators and their methods of identification
GB201312800D0 (en) 2013-07-17 2013-08-28 Heptares Therapeutics Ltd mGlu5 modulators
CA3067688A1 (en) 2017-07-31 2019-02-07 Novartis Ag Use of mavoglurant in the reduction of alcohol use or in preventing relapse into alcohol use
EP3661500B1 (en) * 2017-07-31 2026-01-07 Novartis AG Use of mavoglurant in the reduction of cocaine use or in preventing relapse into cocaine use
EP4181918A2 (en) * 2020-07-17 2023-05-24 Novartis AG Mavoglurant, a mglur5 antagonist, for use in the treatment in the reduction of opioid use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US5543698A (en) * 1994-09-27 1996-08-06 Allen-Bradley Company, Inc. Method and apparatus used with AC motor for detecting unbalance
GB9609976D0 (en) * 1996-05-13 1996-07-17 Lilly Industries Ltd Pharmaceutical compounds
CA2287591A1 (en) * 1997-03-14 1998-09-17 The Johns Hopkins University School Of Medicine Synaptic activation protein compositions and method
TW544448B (en) * 1997-07-11 2003-08-01 Novartis Ag Pyridine derivatives
US6057368A (en) * 1998-08-05 2000-05-02 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
NZ510743A (en) * 1998-10-02 2003-10-31 Novartis Ag mGluR5 antagonists for the treatment of pain and anxiety
TW593241B (en) * 1999-04-20 2004-06-21 Hoffmann La Roche Carbamic acid derivatives
EP1183238A1 (en) * 1999-05-17 2002-03-06 Eli Lilly And Company Metabotropic glutamate receptor antagonists
US6666209B2 (en) * 2001-02-20 2003-12-23 3M Innovative Properties Company Method and system of calibrating air flow in a respirator system

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116981456A (zh) * 2020-12-14 2023-10-31 诺华股份有限公司 mGluR5拮抗剂用于治疗赌博障碍的用途

Also Published As

Publication number Publication date
SE1267869T5 (enExample) 2004-09-07
EP1267869B1 (en) 2004-05-19
ES2220727T3 (es) 2004-12-16
PT1267869E (pt) 2004-10-29
CA2402341A1 (en) 2001-09-13
DE60103384T2 (de) 2005-06-16
NZ521228A (en) 2004-04-30
JP2003525902A (ja) 2003-09-02
AU3763401A (en) 2001-09-17
ATE267013T1 (de) 2004-06-15
SE1267869T3 (enExample) 2004-08-31
TR200401862T4 (tr) 2004-10-21
GB0005700D0 (en) 2000-05-03
AU783869B2 (en) 2005-12-15
EP1267869A1 (en) 2003-01-02
DK1267869T3 (da) 2004-09-20
HK1053262A1 (en) 2003-10-17
DE60103384D1 (de) 2004-06-24
US20030195139A1 (en) 2003-10-16
WO2001066113A1 (en) 2001-09-13

Similar Documents

Publication Publication Date Title
EP1267869B1 (en) Metabotropic glutamate receptor antagonists for the treatment of tolerance and dependance
US12521426B2 (en) Methods and compositions for inhibiting glyoxalase 1 (GLO1)
EP2083811B1 (en) Methods of treating down's syndrome, fragile x syndrome and autism
US8426439B2 (en) Compositions and methods for prophylaxis and treatment of addictions
Zhang et al. Mechanism of opioid addiction and its intervention therapy: Focusing on the reward circuitry and mu‐opioid receptor
JP2001520978A (ja) アンパカインおよび神経遮断薬を用いる精神分裂病の処置
Cao et al. Comparison of pharmacological properties between the kappa opioid receptor agonist nalfurafine and 42B, its 3-dehydroxy analogue: disconnect between in vitro agonist bias and in vivo pharmacological effects
JP2001508797A (ja) ｄ−メタドン、非オピオイド鎮痛剤
JP6002778B2 (ja) アルコール依存症および乱用の治療において使用するためのｏｒｌ−１受容体アンタゴニストとしてのスピロチエノピラン−ピペリジン誘導体
US20110039834A1 (en) Novel pharmaceutical compositions for optimizing substitution treatments and extending the pharmacopoeia to global treatment of addictions
US12551481B2 (en) Molecular targets for addiction
US11241420B2 (en) Compositions and methods for prophylaxis and treatment of addictions
EP2007388A2 (en) Opiopathies
US20230017786A1 (en) Dextromethadone as a disease-modifying treatment for neuropsychiatric disorders and diseases
EP3582764B1 (en) Treatment of alcohol use disorder
JP2010522160A (ja) （Ｒ）−スピロ［１−アザビシクロ［２．２．２］オクタン−３，２’（３’Ｈ）−フロ［２，３−ｂ］ピリジン（ＡＤＺ０３２８）及びアルツハイマー病、ＡＤＨＤ又は認知機能障害の治療におけるその使用
HK1053262B (en) Metabotropic glutamate receptor antagonists for the treatment of tolerance and dependance
US20080090895A1 (en) Novel Pharmaceutical Composition And Their Uses Thereof For Controlling The Different Forms Of Addiction To Drugs
Ikeda Comprehensive studies on pharmacological characteristics of TRK-820, a κ-opioid receptor agonist

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication